The potential interaction between clopidogrel and proton pump inhibitors: A systematic review

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Lima, Joao P D A ^a   Brophy, James M ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PROTON PUMP INHIBITOR; TICLOPIDINE;

ARTICLE; CLINICAL RESEARCH; DATA ANALYSIS; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PUBLICATION; SYSTEMATIC REVIEW; DRUG INTERACTION; REVIEW;

DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 78650958702     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-81     Document Type: Article

References (45)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, . Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502. 10.1056/NEJMoa010746, 11519503, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.
2. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992, 44:527-532. 10.1016/0006-2952(92)90445-O, 1510701.
3. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation 2010, 121:481-483. 10.1161/CIR.0b013e3181d1e0e1, 20083686.
4. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003, 107:32-37. 10.1161/01.CIR.0000047060.60595.CC, 12515739.
5. Martin PT, Denman R. Atorvastatin-clopidogrel interaction. Circulation 2003, 107:e223. 10.1161/01.CIR.0000077528.26542.DC, 12821599.
6. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004, 109:1335-1338. 10.1161/01.CIR.0000124581.18191.15, 15023882.
7. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009, 54:1149-1153. 10.1016/j.jacc.2009.05.050, 19761935.
8. Gilard M, Arnaud B, Cornily JC, Le GG, Lacut K, Le CG, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260. 10.1016/j.jacc.2007.06.064, 18206732.
9. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148. e1-e5, 10.1016/j.ahj.2009.03.015, 19081411.
10. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-484. 10.1177/0091270008315310, 18303127.
11. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944. 10.1001/jama.2009.261, 19258584.
12. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-718. 2659819, 19176635.
13. Food and Drug Adminstration Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009, (accessed Nov 1 2010), Food and Drug Adminstration., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm
14. European Medicines Agency Interaction between clopidogrel and proton-pump inhibitors. 2010, (accessed June 15 2010), European Medicines Agency., http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf
15. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008, 103:2890-2907. 10.1111/j.1572-0241.2008.02216.x, 18853965.
16. Chow CK, Moayyedi P, Devereaux PJ. Is it safe to use a proton pump inhibitor with clopidogrel?. Pol Arch Med Wewn 2009, 119:564-568.
17. Juhasz M, Herszenyi L, Tulassay Z. Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Digestion 2010, 81:10-15. 10.1159/000243717, 20029203.
18. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009, 120:2310-2312. 10.1161/CIRCULATIONAHA.109.907295, 19933929.
19. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009, 43:1266-1274. 10.1345/aph.1M051, 19470853.
20. Zarowitz BJ. Clopidogrel: with or without a proton pump inhibitor?. Geriatr Nurs 2009, 30:188-192. 10.1016/j.gerinurse.2009.03.001, 19520229.
21. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, . STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457. 10.1016/S0140-6736(07)61602-X, 18064739, STROBE Initiative.
22. Cox E, Martin BC, Van ST, Garbe E, Siebert U, Johnson ML. Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009,
23. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 2008, 118:S815.
24. Banerjee S, Varghese C, Weideman R, Weideman M, Little BB. Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel (Abstract P653). Eur Heart J 2009, 30(Suppl):92.
25. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010,
26. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, Berger PB, Steinhubl SR, Topol EJ. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation 2008, 118:S815. (Abstract 3999).
27. Gaspar A, Ribeiro S, Naibas S, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel (Abstract P2679). Eur Heart J 2009, 30(Suppl):444.
28. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010, 55:1964-1968. 10.1007/s10620-009-0960-8, 19731021.
29. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010, 105:1705-1709. 10.1016/j.amjcard.2010.01.348, 20538118.
30. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989-997.
31. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008, 52:1038-1039. 10.1016/j.jacc.2008.05.053, 18786491.
32. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol 2009, 53(Suppl 1):A27.
33. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120:2322-2329. 10.1161/CIRCULATIONAHA.109.873497, 19933932.
34. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010, 152:337-345.
35. Sarafoff N, Sibbing D, Sonntag U, Schulz S, Schoemig A, Kastrati A. Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors (abstr). Eur Heart J 2009, 30(Suppl):150.
36. Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey S. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010, 170:704-710. 10.1001/archinternmed.2010.34, 20421557.
37. Tsiaousis GZ, Zairis MN, Patsourakos N, et al. Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting (abstr). J Am Coll Cardiol 2009, 53(Suppl A):A335.
38. Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C, Gislason G. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010, 153:378-386.
39. Allen MJ, McLean-Veysey P. Interaction between clopidogrel and proton pump inhibitors. CMAJ 2009, 180:1228-1229. 2691442, 19506284.
40. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420. 10.1001/jama.288.19.2411, 12435254.
41. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, . CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717. 10.1056/NEJMoa060989, 16531616, CHARISMA Investigators.
42. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008, 167:492-499. 10.1093/aje/kwm324, 18056625.
43. Altman DG. The scandal of poor medical research. BMJ 1994, 308:283-284. 2539276, 8124111.
44. Anonymous Editorial: Are medical journals getting better-or worse?. Lancet 2009, 374:950. Anonymous.
45. EQUATOR Accessed June 15, 2010, EQUATOR., http://www.equator-network.org/home/